Skip to content

Impact of Long Term of Benzodiazepine Use on Psychiatric Manifestation

Impact of Long Term of Benzodiazepine Use on Psychiatric Manifestation in Neuropsychiatric Disease

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04792658
Enrollment
100
Registered
2021-03-11
Start date
2021-03-10
Completion date
2023-09-20
Last updated
2021-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benzodiazepine-Related Disorders, Psychiatric Disorder

Keywords

psychiatric, benzodiazepine

Brief summary

Benzodiazepines are usually a secondary drug of abuse-used mainly to augment the high received from another drug or to offset the adverse effects of other drugs. Few cases of addiction arise from legitimate use of benzodiazepines. Pharmacologic dependence, a predictable and natural adaptation of a body system long accustomed to the presence of a drug, may occur in patients taking therapeutic doses of benzodiazepines. However, this dependence, which generally manifests itself in withdrawal symptoms upon the abrupt discontinuation of the medication, may be controlled and ended through dose tapering, medication switching, and/or medication augmentation. Due to the chronic nature of anxiety, long-term low-dose benzodiazepine treatment may be necessary for some patients; this continuation of treatment should not be considered abuse or addiction. previous study reported that The results of the study are important in that they corroborate the mounting evidence that a range of neuropsychological functions are impaired as a result of long-term benzodiazepine use, and that these are likely to persist even following withdrawal. The findings highlight the residual neurocognitive compromise associated with long-term benzodiazepine therapy as well as the important clinical implications of these results.

Interventions

BEHAVIORALDetailed interview with personal demographic data

, such as age, sex, education, history of occupation, past medical history, family history, medical, neurological, and psychiatric disorders.

BEHAVIORALIntelligence assessment using the Arabic version of the Wechsler Adult Intelligence Scale (WAIS)

the test consists of six verbal subtests and five performance subtests. It used in measure Intelligence

BEHAVIORALThe Arabic version of the Structured Interview for the Five-Factor Personality Model (SIFFM)

it depend on a model of general language personality descriptors that based on theory suggests five broad dimensions to describe human personality

BEHAVIORALthe Hamilton Depression Rating Scale

it used for evaluation depression severity. It is 17 items and each item's score (0-4). with a total score range of 0-54

BEHAVIORALThe Hamilton Anxiety Rating Scale

it used for evaluation the severity of anxiety. The scale consists of 14 items and each item is scored on a scale from 0 to 4 , with a total score range of 0-56

BEHAVIORALThe Minnesota Multiphasic Personality Inventory-2 (MMPI-2)

It used to evaluate range of symptoms of psychopathology and personality traits that are maladaptive. It has 10 clinical scales subscales included the following: 1, hypochondriasis (Hs); 2, depression (D); 3, hysteria (Hy); 4, psychopathic deviation (Pd); 5, masculinity-femininity (Mf); 6, paranoia (Pa); 7, psychophrenia (Pt); 8, schizophrenia (Sc); 9, hypomania (Ma); 10, social introversion (Ma); (Si). More than 65 responses were considered symptomatic

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* age from 18 years to 50 years * No history of neurological or medical illness

Exclusion criteria

* intelligence score more than 80

Design outcomes

Primary

MeasureTime frame
measure the prevalence of DSM 5 psychiatric disorders associated with long term of benzodiazepine usethrough study completion, an average of 1 year
measure of risk factor of DSM 5 psychiatric disorders associated with long term of benzodiazepine usethrough study completion, an average of 1 year

Contacts

Primary Contactgellan Ahmed
gillankaram@aun.edu.eg+201093663928

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026